Lysosomal Storage Disorders Flashcards

1
Q

Gaucher Type I

A
  • Least severe
  • HSM - enlarged liver and spleen leads to anemia and thrombocytopenia
  • Bone disease
  • Pulmonary tension
  • Little to no neurological symptoms
  • Normal lifespan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Gaucher Type II

A
  • Most severe
  • HSM - enlarged liver and spleen leads to anemia and thrombocytopenia
  • Bone disease
  • Severe neurological symptoms - seizures, opsithotonic posturing
  • Typical lifespan is no longer than 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Gaucher Type III

A
  • Moderate severity
  • HSM -enlarged liver and spleen leads to anemia and thrombocytopeia
  • Bone disease
  • Moderate neurological symptoms - oculomotor apraxia (jarring eye movement, difficulty with peripheral vision), seizures
  • Somewhat limited lifespan, can be extended with treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Gaucher Inheritance/Gene info

A
  • Gene - GBA
  • Chromosome 1
  • Autosomal recessive inheritance
  • Malfunctioning enzyme is glucocerebrosidase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Gaucher Screening and Treatment

A
  • Enzyme and molecular testing
  • Bone marrow biopsy will show enlarged “Gaucher cells”
  • Treatment with enzyme replacement therapy -Cerezyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Gaucher common mutations

A
  • 4 common mutations account for 95% of the population
  • N370S - Associated with Type I
  • D409H - Associated with Type 3 - cardiac calcification is unique to this mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fabry Symptoms

A
  • GI Distress
  • Corneal whorl (does not affect vision)
  • Left ventricular hypertrophy
  • Proteinurea
  • Hypohydrosis - lack of sweat - can lead to easy overheating
  • Acroparathesias - severe pain in hands and feet
  • Gradual hearing lose
  • Depression/Anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Fabry Inheritance/Gene info

A
  • Gene - GLA
  • X Chromosome
  • Can affect females due to skewed X-inactivation
  • X-linked inheritance with affected females (pseudo-dominant)
  • Malfunctioning enzyme is alpha galactosidase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Fabry testing and treatment

A
  • Enzyme testing can be useful on males
  • Enzyme testing is not helpful for females because the enzyme deficiency may be limited, or may not be detected in the blood
  • Molecular testing
  • Symptomatic treatment of pain, cardiac issues, and GI distress with appropriate medication
  • Enzyme replacement therapy with Fabrazyme, Replegal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pompe Disease Symptoms - Infantile Onset

A
  • Cardiomegaly
  • Cardiorespiratory failure
  • Difficulty breathing
  • Muscle weakness (floppy baby)
  • Head lag, delayed motor skills
  • Difficulty feeding, enlarged tongue, hepatomegaly (enlarged liver)
  • Glycogen storage disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pompe Disease Symptoms - Late Onset

A
  • Respiratory difficulty
  • Diaphragmatic weakness
  • Muscle weakness, difficulty walking (these symtpoms can appear to be a type of muscular dystrophy)
  • Difficulty maintaining weight
  • Difficulty swallowing
  • Acid maltase difficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pompe Inheritance/Gene info

A
  • Gene - GAA
  • Chromosome 17
  • Autosomal recessive inheritance
  • Enzyme deficiency is acid alpha glucosidase
  • Glycogen buildup
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pompe testing and treatment

A
  • Enzyme testing
  • Western blot to test for presence of protein
  • Molecular testing
  • Enzyme replacement therapy with myozyme for infants, lumizyme for adults
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mucopolysaccharidoses (MPS)

A
  • Types I-VII with subtypes
  • Leads to improper breakdown of GAGs (glycosaminoglycans), which affect to connective tissue development
  • Can be detected through MPS urine screen, enzyme testing, and molecular testing
  • Regression is a key symptom in most MPS types
  • Skin pebbling occurs due to substrate buildup
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MPS Type I

A
  • Hurler Syndrome- Autosomal Recessive Inheritance
  • Coarse facial features
  • Hepatosplenomegaly
  • Cardiac problems
  • Hydrocephalus
  • Developmental delay
  • Corneal clouding (DOES affect eyesight)
  • Recurrent ENT problems
  • Hearing loss
  • Regression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MPS Type II

A

-Hunter Syndrome - X-linked Inheritance
-Coarse facial features
-Hepatosplenomegaly
-Hydrocephalus
-CLEAR CORNEAS-
-Regression
-Developmental delays
-Hearing loss
-Recurrent ENT problems
-Cardiac problems
SAME AS TYPE I BESIDES BEING X-LINKED AND CLEAR CORNEAS

17
Q

MPS Type III

A
  • Autosomal recessive inheritance
  • Milder skeletal phenotypes
  • Still coarse facial features
  • No associated cardiac problems
  • Progressive sleep and behavioral difficulties
18
Q

MPS Type IV

A
  • Autosomal recessive inheritance
  • Severe skeletal phenotypes
  • Chest deformities
  • Heart problems
  • Short stature
  • Malformed bones
  • Macrocephaly
  • Normal cognitive function
19
Q

MPS Type VI

A
  • Autosomal recessive inheritance
  • Coarse facial features
  • Short stature
  • Corneal clouding
  • Cardiac problems
  • Normal cognitive function
20
Q

MPS Type VII

A
  • Autosomal recessive inheritance
  • Developmental delay
  • Regression
  • Course facial features
  • Hepatosplenomegaly
  • Recurrent ENT problems
  • Cardiac problems
21
Q

MPS Type I and Type II treatments

A
  • Enzyme replacement therapy (does not cross blood/brain barrier)
  • Bone marrow or stem cell transplant before onset of cognitive delay (less efficient in Type II than in Type I)
  • Intrathecal ERT is in trial (enzyme given through the spinal column to access the blood/brain barrier)
22
Q

MPS Type III-VII treatments

A

-Enzyme replacement therapy